BHC Stock Soars As Earnings Beat Fuels Fresh Uptrend

Bausch Health Companies Inc. stocks have been trading up by 11.53 percent amid strong positive sentiment on improved earnings outlook.

Live Update At 12:33:52 EDT: On Friday, July 31, 2026 Bausch Health Companies Inc. stock [NYSE: BHC] is trending up by 11.53%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Bausch Health Companies Inc. just reminded the market that ugly balance sheets can still power big moves when earnings turn. In Q2 2026, BHC posted non-GAAP EPS of $1.26 versus the $1.01 consensus and revenue of $2.85B against $2.66B expected. That beat locked in the company’s 13th straight quarter of year-over-year revenue and adjusted EBITDA growth, excluding Bausch + Lomb.

The income statement shows total revenue of $2.852B, gross profit of the same amount, and EBITDA of about $1.046B, translating to an 18.7% EBITDA margin. Net income was $258M, helped by strong operating leverage even with heavy interest expense of $396M. On the cash side, BHC generated $670M in operating cash flow and $593M in free cash flow in the quarter, while trimming net debt and ending with $1.825B in cash and equivalents.

More Breaking News

• RAM ETF Slides From Highs As Volatility Stays Elevated
• KPTI Stock Collapses After Trial Failure And Legal Scrutiny
• KPTI Stock Craters As Trial Failure And Legal Scrutiny Hit
• Nebius Group NBIS Stock Jumps On $1B AI Deal

At the same time, BHC still carries roughly $19.9B in long-term debt and negative common equity of about -$1.77B. So this is very much a high-debt, turnaround-style story, but now with clear evidence of improving fundamentals that traders can track quarter by quarter.

Why Traders Are Watching BHC After The Breakout

The market didn’t shrug this off. Bausch Health shares exploded about 26%–27% after the Q2 beat and the raised 2026 outlook, turning a sleepy mid-$4 stock into a momentum name almost overnight. The daily chart shows BHC grinding between roughly $4.40 and $4.90 for weeks, then launching from a $4.97 open on 2026/07/30 to close at $6.03. The next day, BHC extended to a $6.73 high and finished near the top of the range at $6.73.

Intraday, the 5‑minute tape reads like a classic earnings breakout. BHC opened at $6, pushed quickly into the low $6.20s, then built a steady series of higher lows, marching from roughly $6.30 at 09:40 toward $6.70+ after midday. That’s orderly trend action, not a random spike. For day traders, this is the kind of clean staircase you look for when momentum funds and shorts are battling in real time.

Under the hood, Bausch Health is trying to fix a highly leveraged structure. The balance sheet shows $24.8B in assets, $25.6B in liabilities, and negative equity, but the company is paying down debt and expanding EBITDA. Management’s 2026 guidance of $10.79B–$11.04B in revenue and $4.05B–$4.175B in adjusted EBITDA tells the market they expect this trajectory to continue.

Still, BHC isn’t a simple growth story. RBC Capital keeps a Sector Perform rating with a $9 price target, pointing to Xifaxan patent litigation and possible monetization of Bausch + Lomb as key catalysts. For traders, that’s a roadmap: watch court headlines, any Bausch + Lomb moves, and forex chatter as possible triggers for the next big swing in BHC.

Conclusion

For active traders, Bausch Health Companies Inc. is shifting from “left for dead” to “prove‑it breakout.” The Q2 2026 numbers — a non-GAAP EPS beat, $2.85B in revenue, strong free cash flow, and meaningful net‑debt reduction — back up the price action. BHC is not running on hopes alone; the income statement and cash flow statement now show real progress.

But the risk profile of BHC is still elevated. Long‑term debt near $19.9B, negative equity, and ongoing Xifaxan patent litigation keep this a volatile name. Guidance out to 2026 looks constructive, with revenue and adjusted EBITDA both guided above consensus, yet traders need to remember that long‑range targets only matter if each quarter supports the story.

This is where discipline comes in. The recent 26%–27% surge has already repriced BHC from the mid‑$4s into the mid‑$6s, and late chasers will be dealing with wider ranges and heavier headline risk. In the words often repeated by Tim Sykes, “The market doesn’t care about your opinion, it cares about your risk management.” As Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” For anyone trading Bausch Health, that means respecting the volatility, planning exits before entries, and letting the earnings tape — not emotions — drive every decision.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.